COMPANY

TVAX Biomedical

Keywords: oncology cancer Glioblastoma Multiforme Glioblastoma Multiforme of Brain Recurrent Glioblastoma Grade IV Glioma Grade IV Astrocytoma Glioma High Grade Astrocytoma TVI-Brain 1

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Timeline

Dec 27, 2023 Trial start Phase 2/Phase 3: Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) source ↗
2011-06 Trial start Phase 2: Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma source ↗
2010-04 Trial start I: Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma source ↗

Upcoming milestones

2030-11 (ESTIMATED) · Phase 2/Phase 3 · Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) · NCT05685004

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT05685004	Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)	Phase 2/Phase 3	Active, not recruiting	Dec 27, 2023	2030-11 (estimated)
NCT05936216	TVI-Brain-1 in Expanded Access Patient	Not listed	No longer available	Not listed	Not listed
NCT01290692	Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma	Phase 2	Completed	2011-06	2013-12 (actual)
NCT01081223	Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma	I	Completed	2010-04	2011-03 (actual)